ACIU AC Immune SA IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1651625 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | 2025Q2*2025-06-30 | 2024Q2*2024-06-30 | 2023Q2*2023-06-30 | 2022Q4*2022-12-31 | 2022Q3*2022-09-30 | 2022Q2*2022-06-30 | 2021Q4*2021-12-31 | 2021Q3*2021-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 1.31M | 687,000 | 0 | 1,000 | 3.93M | 0 | 0 | 0 |
| R&D expense | 16.83M | 17.14M | 13.68M | 15.14M | 14.38M | 15.69M | 20.12M | 15.12M |
| SG&A expense | 3.90M | 4.55M | 3.68M | 3.96M | 3.27M | 4.37M | 2.92M | 5.42M |
| Operating income | -19.39M | -20.96M | -17.05M | -18.70M | -13.46M | -19.86M | -22.79M | -20.28M |
| Interest expense | 50,000 | 34,000 | 27,000 | -1,000 | 77,000 | 126,000 | 173,000 | 181,000 |
| Pretax income | -21.19M | -22.76M | -16.83M | -18.75M | -13.51M | -19.64M | -21.27M | -15.92M |
| Income tax | — | — | 3,000 | 2,000 | 4,000 | 3,000 | — | — |
| Net income | -21.19M | -22.76M | -16.83M | -18.75M | -13.52M | -19.64M | -21.28M | -15.92M |
| EPS (basic) | -0.21 | -0.23 | -0.20 | — | -0.16 | -0.23 | — | -0.22 |
| EPS (diluted) | -0.21 | -0.23 | -0.20 | — | -0.16 | -0.23 | — | -0.22 |
| Weighted avg. shares (diluted) | 100.63M | 99.55M | 84.61M | — | 83.59M | 84.46M | — | 72.89M |
| Balance sheet | ||||||||
| Cash & equivalents | 25.72M | 51.56M | 40.01M | 31.59M | 44.50M | 63.15M | 82.22M | 93.58M |
| Short-term investments | 101.41M | 123.56M | 53.00M | 91.00M | — | — | 116.00M | — |
| Receivables | — | 0 | — | — | — | — | — | — |
| Current assets | 131.81M | 180.54M | 99.15M | 128.09M | 147.60M | — | 202.63M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 2.49M | 2.93M | 3.76M | 4.26M | 4.69M | — | 5.12M | — |
| Intangibles | 50.42M | 50.42M | 50.42M | 50.42M | 50.42M | — | 50.42M | — |
| Total assets | 190.22M | 237.53M | 156.23M | 185.94M | 205.56M | — | 261.44M | — |
| Current liabilities | 98.97M | 100.53M | 11.15M | 11.48M | 13.60M | — | 20.03M | — |
| Total liabilities | 115.48M | 114.11M | 16.90M | 16.95M | 15.50M | — | 29.46M | — |
| Shareholders' equity | 74.74M | 123.42M | 139.33M | 168.99M | 190.05M | 202.81M | 231.98M | 179.22M |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | -17.41M | -13.54M | — | -17.83M | — |
| Capital expenditure | — | — | — | 41,000 | 121,000 | — | 722,000 | — |
| Free cash flow | — | — | — | -17.45M | -13.66M | — | -18.55M | — |
| Investing cash flow | — | — | — | 4.96M | -5.12M | — | -21.72M | — |
| Financing cash flow | — | — | — | -151,000 | -142,000 | — | 28.73M | — |
| Stock-based compensation | 1.10M | 1.40M | — | 889,000 | 555,000 | — | 1.04M | — |
Free plan shows the latest 8 periods; Pro shows all 16 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.